Abstract #2569

Evaluating the Role of PIRADS V2 and TRUSgBX for Improving Detection of Clinically Significant Prostate Cancer at Radical Prostatectomy

Alireza Ziaei¹, Francesco Alessandrino^1,2, Mark Vangel³, Tina Kapur¹, Clare Mary Tempany¹, and Fiona Mary Fennessy^1,2

¹Dept. of Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States, ²Dept. of Imaging, Dana–Farber Cancer Institute, Boston, MA, United States, ³Dept. of Radiology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, United States

The aim of this retrospective study was to determine a role for PIRADS V2 in conjunction with TRUSgBX to predict the presence of clinically significant prostate cancer (csPCa) in treatment naïve men with pathology-proven prostate cancer who underwent TRUSgBX, followed by 3T mp-MRI prostate, and subsequently underwent RP. Our findings suggest that adding PIRADS V2 assessment to TRUSgBX improves the prediction of final pathology for presence of indolent disease and csPCa, and may help alleviate the rate of upgrading at RP.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.